🇺🇸 FDA
Patent

US 8378071

Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis

granted A61KA61K38/00A61P

Quick answer

US patent 8378071 (Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Feb 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61P, A61P19/10, A61P29/00